Real-time PCR and high-resolution melt analysis for rapid detection of Mycobacterium leprae drug resistance mutations and strain types

实时 PCR 和高分辨率熔解分析快速检测麻风分枝杆菌耐药突变和菌株类型

阅读:16
作者:Wei Li, Masanori Matsuoka, Masanori Kai, Pratibha Thapa, Saraswoti Khadge, Deanna A Hagge, Patrick J Brennan, Varalakshmi Vissa

Abstract

Drug resistance surveillance and strain typing of Mycobacterium leprae are necessary to investigate ongoing transmission of leprosy in regions of endemicity. To enable wider implementation of these molecular analyses, novel real-time PCR-high-resolution melt (RT-PCR-HRM) assays without allele-specific primers or probes and post-PCR sample handling were developed. For the detection of mutations within drug resistance-determining regions (DRDRs) of folP1, rpoB, and gyrA, targets for dapsone, rifampin, and fluoroquinolones, real-time PCR-HRM assays were developed. Wild-type and drug-resistant mouse footpad-derived strains that included three folP1, two rpoB, and one gyrA mutation types in a reference panel were tested. RT-PCR-HRM correctly distinguished the wild type from the mutant strains. In addition, RT-PCR-HRM analyses aided in recognizing samples with mixed or minor alleles and also a mislabeled sample. When tested in 121 sequence-characterized clinical strains, HRM identified all the folP1 mutants representing two mutation types, including one not within the reference panel. The false positives (<5%) could be attributed to low DNA concentration or PCR inhibition. A second set of RT-PCR-HRM assays for identification of three previously reported single nucleotide polymorphisms (SNPs) that have been used for strain typing were developed and validated in 22 reference and 25 clinical strains. Real-time PCR-HRM is a sensitive, simple, rapid, and high-throughput tool for routine screening known DRDR mutants in new and relapsed cases, SNP typing, and detection of minor mutant alleles in the wild-type background at lower costs than current methods and with the potential for quality control in leprosy investigations.

文献解析

1. 文献背景信息

  • ​标题/作者/期刊/年份​​:

    Real-time PCR and high-resolution melt analysis for rapid detection of Mycobacterium leprae drug resistance mutations and strain types

    • ​期刊​​:Journal of Clinical Microbiology(IF=6.100,微生物学领域权威期刊)

    • ​年份​​:2012(时效性需注意,但方法学可能仍具参考价值)

    • ​作者​​:国际团队(含麻风病研究专家Masanori Matsuoka等)。

  • ​研究领域与背景​​:

    • ​分支领域​​:麻风分枝杆菌(M. leprae)的耐药性监测和分子分型技术。

    • ​研究现状​​:当时麻风病耐药突变检测依赖测序或探针法,成本高、耗时长;菌株分型需多步骤PCR。

  • ​研究动机​​:

    • ​空白​​:缺乏快速、低成本、高通量的耐药突变和分型检测方法。

    • ​目标​​:开发无需探针/测序的实时PCR-高分辨率熔解曲线分析(RT-PCR-HRM)技术。


2. 研究问题与假设

  • ​核心问题​​:如何通过简化技术流程实现麻风分枝杆菌耐药突变和菌株分型的快速筛查?

  • ​假设​​:HRM可通过熔解曲线差异区分野生型与突变型,且能检测混合等位基因。


3. 研究方法学与技术路线

  • ​实验设计​​:方法学开发+临床验证。

    • ​参考样本​​:小鼠足垫培养的耐药菌株(含folP1rpoBgyrA突变)和121例临床菌株。

  • ​关键技术​​:

    • ​RT-PCR-HRM​​:针对耐药决定区(DRDRs)和分型SNPs设计引物,通过熔解温度(Tm)差异区分突变。

  • ​创新点​​:

    • 首次将HRM应用于麻风病耐药检测,无需探针/测序,降低成本。

    • 可识别混合感染和低丰度突变(灵敏度高)。


4. 结果与数据解析

  • ​主要发现​​:

                   HRM准确区分所有参考菌株的耐药突变(如folP1Thr53Ile、rpoBSer456Leu)。

                   临床验证中检出全部已知突变(包括未纳入参考的新突变),假阳性率<5%(与DNA质量相关)。

                   分型SNP检测与测序结果一致(22参考株+25临床株)。

  • ​局限性​​:

    • 仅覆盖已知突变,新突变需测序确认。

    • 临床样本中PCR抑制物可能影响结果。


5. 讨论与机制阐释

  • ​机制解释​​:突变导致DNA Tm值改变,HRM通过曲线形态差异识别。

  • ​与既往对比​​:

    • 比传统测序/探针法更快捷、经济,适合资源有限地区。

    • 支持麻风病耐药突变谱的简化监测策略。

  • ​未解决问题​​:需扩大突变检测范围,优化临床样本处理流程。


6. 创新点与学术贡献

  • ​技术贡献​​:

    • 提供麻风病耐药筛查的高通量方案,可推广至其他病原体(如结核分枝杆菌)。

  • ​实际价值​​:

    • 助力麻风病流行区的耐药监测和传播链追踪。

    • 为混合感染研究提供工具(如检测野生型背景中的低频突变)。


总结

该文献开发了一种经济高效的HRM方法,解决了麻风病耐药检测的技术瓶颈,但需结合测序验证新突变。其技术思路对其他病原体研究具有借鉴意义。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。